drugset / Trial / NCT05751343
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
Atezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for those patients is still unknown. This phase 2 clinical trial aims to investigate the objective response rate for unresectable advanced hepatocellular carcinoma.
Timeline
- Start
- 2023-03-09
- Primary completion
- 2024-08-28
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Epirubicin | Small molecule | 30 mg/m2 | Other |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 1200 mg/m2 | Other |